PET Identifies Tangles Decades after a Single Traumatic Brain Injury
The pattern varied from person to person, depending on the site of injury, in contrast to the stereotyped distribution of tau tangles seen in Alzheimer’s disease.
ALL NEWS
428 RESULTS
Sort By:
- Most Recent
- Most Commented
In Alzheimer’s, More TREM2 Is Good for You
Longitudinal ADNI data tie higher sTREM2 in CSF to slower cognitive decline, reinforcing the idea that TREM2 activity protects the brain from AD pathology.
Proteomics Uncovers Potential Markers, Subtypes of Alzheimer’s
Changes in the composition of the cerebrospinal fluid and synapses may reveal novel insights into AD pathology.
Synaptic Proteins in CSF: New Markers of Cognitive Decline?
Protein levels track with cognitive function and can distinguish Alzheimer’s patients from controls.
Why Bother With Round Robins on Blood Tests? Q&A with Kaj Blennow
What’s with all those head-to-head comparison studies of academic and commercial biomarker tests? Could we not just pick one that works, and be done?
Are Aβ Blood Tests Ready for Prime Time?
A plasma assay for Alzheimer’s could radically speed up screening for clinical trials; alas, competing assays don’t measure the same thing.
Move Over CSF, P-Tau in Blood Also Tells Us There’s Plaque in the Brain
At this year’s AAIC, no sooner had scientists reported that phospho-tau in the CSF might reflect early responses to amyloid, than they reported parallel data for phospho-tau in blood.
Move Over Aβ, CSF P-Tau Tells Us There’s Plaque in the Brain
At AAIC, researchers touted phospho-tau species, especially p217 and p181. They tick up in CSF as an early response to amyloid accumulation.
Colombian Cohort Delivers Data on Blood NfL
In 2,144 Colombian ADAD family members, plasma NfL in gene carriers rises as early as two decades before their symptoms start.
Crenezumab Update: Baseline Data from Colombian Prevention Trial
At AAIC, researchers presented baseline data from an ongoing, five-year study asking whether the anti-Aβ antibody crenezumab can forestall cognitive decline in autosomal-dominant Alzheimer’s disease.
New PET Staging Scheme for Amyloid?
Longitudinal data identifies four stages of amyloid plaque buildup, with the earliest deposits appearing in the precuneus and posterior cingulate.
Can Researchers Detect Dementia With Lewy Bodies at the Prodromal Stage?
The field is searching for a combination of clinical features and biomarkers that will identify the disease in people with mild cognitive impairment.
Does Serotonin Pathology Foreshadow Parkinson’s Disease?
In carriers of a PD-causing mutation, PET scans showed serotonin transporter loss before motor symptoms set in.
Drawing Closer: Alzheimer’s Blood Test for Primary Care
Fully automated immunoassay could offer cost-effective screening for AD.
NfL: Useful in Differential Diagnosis?
A meta-analysis of 47 studies suggests CSF NfL is particularly elevated in a select few, suggesting it could help in differential diagnosis.
Current Filters
- Biomarkers x